تحميل...
IMMU-20. ADVANCED AGING INCREASES IMMUNOSUPPRESSIVE IDO1 LEVELS THAT ARE UNINHIBITED BY IDO1 ENZYME INHIBITOR TREATMENT IN MODELS OF GLIOBLASTOMA
Immunotherapy has failed to improve the overall survival (OS) of adults with GBM in all phase III clinical trials to-date. Somewhat less appreciated is that, de novo GBM is a disease associated with a median age of diagnosis at 64 years old. Because of the strong association between advanced aging a...
محفوظ في:
| الحاوية / القاعدة: | Neuro Oncol |
|---|---|
| المؤلفون الرئيسيون: | , , , , , , |
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
Oxford University Press
2019
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6847513/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.513 |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|